• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

News

Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study

2 de October de 2021
Clin Cancer Res. 2021 Dec 15;27(24):6677-6686. doi: 10.1158/1078-0432.CCR-21-2199.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-10-02 10:00:002021-10-02 10:00:00Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study

High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer

1 de October de 2021
Clin Cancer Res. 2022 Jan 1;28(1):137-149. doi: 10.1158/1078-0432.CCR-21-1810.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-10-01 10:00:002021-10-01 10:00:00High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer

Visions for a JACIE Quality Management System 4.0

30 de September de 2021
Bone Marrow Transplant. 2021 Dec;56(12):2876-2881. doi: 10.1038/s41409-021-01467-8.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-09-30 10:00:002021-09-30 10:00:00Visions for a JACIE Quality Management System 4.0

Whey-Derived Porous Carbon Scaffolds for Bone Tissue Engineering

28 de September de 2021
Biomedicines. 2021 Aug 26;9(9):1091. doi: 10.3390/biomedicines9091091.ABSTRACTPorous…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-09-28 10:00:002021-09-28 10:00:00Whey-Derived Porous Carbon Scaffolds for Bone Tissue Engineering

Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629

24 de September de 2021
Dermatol Ther (Heidelb). 2021 Oct;11(5):1777-1790. doi: 10.1007/s13555-021-00598-6.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-09-24 10:00:002021-09-24 10:00:00Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

22 de September de 2021
N Engl J Med. 2021 Sep 23;385(13):1196-1206. doi: 10.1056/NEJMoa2103485.ABSTRACTBACKGROUND:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-09-22 10:00:002021-09-22 10:00:00Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

A single-cell tumor immune atlas for precision oncology

22 de September de 2021
Genome Res. 2021 Oct;31(10):1913-1926. doi: 10.1101/gr.273300.120.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2021-09-22 10:00:002021-09-22 10:00:00A single-cell tumor immune atlas for precision oncology

Translational medicine in hereditary hemorrhagic telangiectasia

20 de September de 2021
Eur J Intern Med. 2022 Jan;95:32-37. doi: 10.1016/j.ejim.2021.09.003.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-09-20 10:00:002021-09-20 10:00:00Translational medicine in hereditary hemorrhagic telangiectasia

Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives

13 de September de 2021
Cancer Lett. 2021 Dec 28;523:162-169. doi: 10.1016/j.canlet.2021.08.033.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-09-13 10:00:002021-09-13 10:00:00Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives

Ultralight-Weight Graphene Aerogels with Extremely High Electrical Conductivity

12 de September de 2021
Small. 2021 Oct;17(41):e2103407. doi: 10.1002/smll.202103407.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-09-12 10:00:002021-09-12 10:00:00Ultralight-Weight Graphene Aerogels with Extremely High Electrical Conductivity

Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective

9 de September de 2021
Ther Adv Med Oncol. 2021 Sep 2;13:17588359211042224. doi: 10.1177/17588359211042224.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-09-09 10:00:002021-09-09 10:00:00Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective

Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation

8 de September de 2021
Blood Adv. 2021 Sep 14;5(17):3418-3426. doi: 10.1182/bloodadvances.2021004812.ABSTRACTThe…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2021-09-08 10:00:002021-09-08 10:00:00Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation
Page 36 of 87«‹3435363738›»

Filter by categories

  • Alemany’s & Piulats’s lab (133)
  • Antolin's lab (36)
  • Aytes's Lab (25)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (110)
  • Sin categoría (5)
  • Sureda's & Farre's Lab (312)
  • Viñals's lab (111)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}